Unité de Fabrication des Médicaments Past Earnings Performance
Past criteria checks 4/6
Unité de Fabrication des Médicaments's earnings have been declining at an average annual rate of -20.3%, while the Pharmaceuticals industry saw earnings growing at 7.8% annually. Revenues have been growing at an average rate of 1.6% per year. Unité de Fabrication des Médicaments's return on equity is 13.8%, and it has net margins of 11.4%.
Key information
-20.3%
Earnings growth rate
-20.3%
EPS growth rate
Pharmaceuticals Industry Growth | 12.4% |
Revenue growth rate | 1.6% |
Return on equity | 13.8% |
Net Margin | 11.4% |
Last Earnings Update | 30 Jun 2023 |
Recent past performance updates
Recent updates
Revenue & Expenses BreakdownBeta
How Unité de Fabrication des Médicaments makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
30 Jun 23 | 115 | 13 | 18 | 0 |
31 Mar 23 | 106 | 10 | 17 | 0 |
31 Dec 22 | 96 | 8 | 17 | 0 |
30 Sep 22 | 91 | 6 | 17 | 0 |
30 Jun 22 | 86 | 5 | 17 | 0 |
31 Mar 22 | 85 | 7 | 16 | 0 |
31 Dec 21 | 85 | 9 | 15 | 0 |
30 Sep 21 | 85 | 7 | 15 | 0 |
30 Jun 21 | 86 | 6 | 15 | 0 |
31 Mar 21 | 89 | 7 | 15 | 0 |
31 Dec 20 | 91 | 7 | 15 | 0 |
30 Sep 20 | 93 | 10 | 15 | 0 |
30 Jun 20 | 95 | 12 | 15 | 0 |
31 Mar 20 | 101 | 15 | 15 | 0 |
31 Dec 19 | 107 | 18 | 15 | 0 |
30 Sep 19 | 107 | 20 | 15 | 0 |
30 Jun 19 | 107 | 22 | 14 | 0 |
31 Mar 19 | 97 | 20 | 14 | 0 |
31 Dec 18 | 87 | 18 | 13 | 0 |
30 Sep 18 | 80 | 16 | 13 | 0 |
30 Jun 18 | 73 | 13 | 13 | 0 |
31 Mar 18 | 72 | 13 | 13 | 0 |
31 Dec 17 | 70 | 13 | 12 | 0 |
30 Sep 17 | 69 | 12 | 12 | 0 |
30 Jun 17 | 68 | 11 | 11 | 0 |
31 Mar 17 | 66 | 11 | 11 | 0 |
31 Dec 16 | 65 | 11 | 10 | 0 |
30 Sep 16 | 63 | 13 | 10 | 0 |
30 Jun 16 | 61 | 15 | 9 | 0 |
31 Mar 16 | 60 | 14 | 9 | 0 |
31 Dec 15 | 59 | 13 | 9 | 0 |
30 Sep 15 | 60 | 12 | 9 | 0 |
30 Jun 15 | 60 | 11 | 8 | 0 |
31 Mar 15 | 59 | 12 | 8 | 0 |
31 Dec 14 | 58 | 12 | 8 | 0 |
31 Dec 13 | 47 | 10 | 8 | 0 |
Quality Earnings: UMED has high quality earnings.
Growing Profit Margin: UMED's current net profit margins (11.4%) are higher than last year (5.9%).
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: UMED's earnings have declined by 20.3% per year over the past 5 years.
Accelerating Growth: UMED's earnings growth over the past year (158.3%) exceeds its 5-year average (-20.3% per year).
Earnings vs Industry: UMED earnings growth over the past year (158.3%) exceeded the Pharmaceuticals industry -4.8%.
Return on Equity
High ROE: UMED's Return on Equity (13.8%) is considered low.